BIMI International Medical, Inc.

  • Market Cap: N/A
  • Industry: Retailing
  • ISIN: US05552Q3011
USD
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

240

Shareholding (Dec 2023)

FII

0.06%

Held by 1 FIIs

DII

99.88%

Held by 0 DIIs

Promoter

0.00%

Who are in the management team of BIMI International Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of BIMI International Medical, Inc. includes Mr. Yongquan Bi (Chairman), Tiewei Song (CEO), and Directors Gang Li, Ju Li, Fengsheng Tan, and Independent Director Mia Kuang Ching. They oversee the company's operations and strategic direction.

As of March 2022, the management team of BIMI International Medical, Inc. includes the following individuals:<BR><BR>- Mr. Yongquan Bi, Chairman of the Board<BR>- Tiewei Song, Chief Executive Officer and Director<BR>- Mr. Gang Li, Director<BR>- Mr. Ju Li, Director<BR>- Fengsheng Tan, Director<BR>- Mr. Mia Kuang Ching, Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Read More

Is BIMI International Medical, Inc. technically bullish or bearish?

25-Jun-2025

As of November 1, 2023, there is not enough technical data for BIMI International Medical, Inc. to determine a bullish or bearish outlook.

As of 1 November 2023, the technical data for BIMI International Medical, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is BIMI International Medical, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, BIMI International Medical, Inc. is considered overvalued with a price-to-earnings ratio of 25.4, significantly higher than peers like HCA Healthcare and Tenet Healthcare, and its stock performance has not exceeded the Sensex.

As of 1 October 2023, BIMI International Medical, Inc. has moved from fair to overvalued. The company's current price-to-earnings ratio stands at 25.4, while its price-to-book ratio is 3.1, and the price-to-sales ratio is 5.6, indicating a premium valuation compared to its earnings and assets. <BR><BR>In comparison to peers such as HCA Healthcare, which has a price-to-earnings ratio of 15.2, and Tenet Healthcare with a price-to-sales ratio of 0.6, BIMI's ratios suggest it is overvalued in the current market environment. Recent stock performance has not outpaced the Sensex, further reinforcing the notion that the stock may be priced too high relative to its fundamentals.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Retailing

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.12

stock-summary
Return on Equity

-75.05%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Sep 2023)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
-66.67%
0%
-66.67%
1 Year
-98.67%
0%
-98.67%
2 Years
-99.99%
0%
-99.99%
3 Years
-99.96%
0%
-99.96%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

BIMI International Medical, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
16.91%
EBIT Growth (5y)
-210.31%
EBIT to Interest (avg)
-6.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
1.16
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.52%
ROCE (avg)
0
ROE (avg)
3.59%
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
0.00
EV to EBIT
-0.24
EV to EBITDA
-0.25
EV to Capital Employed
0.11
EV to Sales
0.06
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-44.80%
ROE (Latest)
-75.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (0.06%)

Foreign Institutions

Held by 1 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is -65.75% vs -47.10% in Sep 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 16.22% vs -117.65% in Sep 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.50",
          "val2": "7.30",
          "chgp": "-65.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.10",
          "val2": "-3.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.10",
          "val2": "-3.70",
          "chgp": "16.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,248.30%",
          "val2": "-422.70%",
          "chgp": "-82.56%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is -56.46% vs 111.72% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 38.11% vs -818.42% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.80",
          "val2": "27.10",
          "chgp": "-56.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.70",
          "val2": "-7.90",
          "chgp": "-22.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.40",
          "val2": "0.40",
          "chgp": "750.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.40",
          "val2": "-26.10",
          "chgp": "79.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.60",
          "val2": "-34.90",
          "chgp": "38.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-841.30%",
          "val2": "-299.40%",
          "chgp": "-54.19%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'23 - YoYstock-summary
Sep'23
Sep'22
Change(%)
Net Sales
2.50
7.30
-65.75%
Operating Profit (PBDIT) excl Other Income
-3.10
-3.10
Interest
0.00
0.20
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.10
-3.70
16.22%
Operating Profit Margin (Excl OI)
-1,248.30%
-422.70%
-82.56%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2023 is -65.75% vs -47.10% in Sep 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2023 is 16.22% vs -117.65% in Sep 2022

Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
11.80
27.10
-56.46%
Operating Profit (PBDIT) excl Other Income
-9.70
-7.90
-22.78%
Interest
3.40
0.40
750.00%
Exceptional Items
-5.40
-26.10
79.31%
Consolidate Net Profit
-21.60
-34.90
38.11%
Operating Profit Margin (Excl OI)
-841.30%
-299.40%
-54.19%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is -56.46% vs 111.72% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 38.11% vs -818.42% in Dec 2021

stock-summaryCompany CV
About BIMI International Medical, Inc. stock-summary
stock-summary
BIMI International Medical, Inc.
Retailing
BOQI INTERNATIONAL MEDICAL INC is a company engaged in pharmacy business. The Company has directly owned stores under the brand Boqi Pharmacy in China, and it sells medicines and other health-related products through the stores. The products sold are mainly comprised of prescription drugs, over-the-counter (OTC) drugs, nutritional supplements, sundry products and medical devices.
Company Coordinates stock-summary
Company Details
3105 Tower C, 390 Qingnian Avenue, Heping District SHENYANG LIA : 116000
stock-summary
Tel: 86 411 82209211
stock-summary
Registrar Details